Resilient Performance Group LLC — Founder and Principal (September 2025 – Present)

Life sciences strategic advisory. Rare disease commercial strategy, market access, medical affairs, and global launch. Based in Brick Township, Ocean County, New Jersey.

ResilExec® Coaching — Founder and Executive Coach (October 2025 – Present)

Executive advancement coaching for Directors and VPs in healthcare, life sciences, and enterprise IT. Flagship program: the Purpose-Driven Ascent™.

Azurity Pharmaceuticals — VP, Franchise Portfolio Management, Cardiometabolics, Ophthalmology, Respiratory (October 2024 – September 2025)

Led commercial strategy and cross-functional governance across a multi-brand portfolio. Supported lifecycle management, business development assessment, and pipeline sustainability planning.

Otsuka Pharmaceutical Companies (U.S.) — Executive Director, Marketing, Nephrology and Rare Disease, sibeprenlimab (February 2024 – May 2024)

Commercial strategy leadership for nephrology and rare disease pipeline assets.

Novartis — Vice President, Senior General Manager, Rare Renal, iptacopan (May 2022 – February 2024)

Led rare disease business unit development, field operations, and commercial strategy for iptacopan across IgA nephropathy, PNH, and C3G. 250-person organization. Recipient of the Novartis President's Award — Top 5 US Leaders (Sales Performance, People Development, Leadership, and Employee Retention).

The full personal narrative of Brian Baldari's career — told through the lens of the purpose driving it — is at brianbaldarinj.com.

Novartis — Executive Director, Marketing, Rare Renal, iptacopan (December 2020 – May 2022)

Led commercialization strategy and cross-functional budget management across rare renal portfolio.

Novartis — Senior Global Marketing Director, Retina, Beovu (April 2019 – December 2020)

Spearheaded global strategic marketing for the wet AMD indication launch in China and emerging markets. Crafted global commercial strategy for all lifecycle management indications — DME, RVO, PDR. Developed annual global P&L and operating plans. Recognized with the Global Culture Award for global emerging market strategy.

Novartis — Worldwide New Products Marketing Director, Cardiometabolics (February 2018 – March 2019)

Secured approval for Full Development Plan of pelacarsen for reducing lipoprotein(a) levels. Led Business Development and Licensing acquisition of pelacarsen from Ionis Pharmaceuticals and divestiture of abelacimab to Anthos Therapeutics. Evaluated 30+ in-licensing opportunities.

Allergan — Director, Women's Health Marketing (November 2016 – February 2018)

Led Esmya brand launch in uterine fibroids, implementing the full marketing plan in under 12 months. Orchestrated Women's Health Key Opinion Leader engagement plan with 30+ industry leaders. Led team of 3 professionals.

Boehringer Ingelheim — Director, Managed Markets Marketing (December 2015 – November 2016)

Led Managed Markets Marketing strategy across diabetes portfolio with payer and health system customers. Established the Payer and Health System Marketing function at Boehringer Ingelheim.

Boehringer Ingelheim — Director, Global Pipeline Marketing, Obesity, Cardiology, Renal, and Metabolism (March 2013 – November 2015)

Led global pipeline commercial strategy across obesity, cardiovascular, renal, and metabolic therapeutic areas. Recipient of the Lead and Learn Marketing Excellence Award, Marketing Rock Star Award, and Top Performer Award.

Boehringer Ingelheim — Associate Director, Diabetes HCP Marketing (November 2011 – February 2013)

Led HCP marketing execution for Tradjenta, driving significant market share growth.

Boehringer Ingelheim — Senior Product Manager, HCP Marketing, P2P and Digital (June 2010 – November 2011)

Supported launch of new diabetes products with responsibility for omnichannel promotion including digital and media strategy.

Boehringer Ingelheim — Product Manager, HCP Marketing, KOL and MedEd (August 2008 – July 2010)

Key opinion leader engagement and medical education strategy for diabetes portfolio.

Boehringer Ingelheim — Associate Director, Medical Science Liaisons (February 2006 – August 2008)

Led a field medical team including regional managers and Medical Science Liaisons in support of a specialty product launch.

Boehringer Ingelheim — Medical Science Liaison (August 2004 – January 2006)

New York City metropolitan area. Field medical engagement for specialty therapeutic area.

Watson Pharmaceuticals — Medical Information Specialist (July 2002 – July 2004)

Morristown, New Jersey. Clinical and medical information support. Career foundation.